Abliva
0,242SEK +2,33%Vær den første som følger denne virksomhed
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Omsætning
30 t
EBIT %
-277.300 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ABLI
Daglig lav / høj pris
0,231 / 0,249
SEK
Markedsværdi
255,62 mio. SEK
Aktieomsætning
484,45 t SEK
Volumen
2 mio.
Finanskalender
Årsrapport
23.02.2024
Generalforsamling
23.05.2024
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Hadean Capital I AS | 22,4 % | 22,4 % |
| Oslo Pensjonsforsikring AS | 14,9 % | 14,9 % |
Premium
Not activated
This content is for our Premium customers only.
ViserAlle indholdstyper